Clinical trials that target human endogenous retroviruses to treat multiple sclerosis, ALS, and other ailments are underway, but many questions remain about how these sequences may disrupt our biology.
Brianna Chrisman and Jordan Eizenga | Sep 1, 2022 | 10+ min read
Thirty years out from the start of the Human Genome Project, researchers have finally finished sequencing the full 3 billion bases of a person’s genetic code. But even a complete reference genome has its shortcomings.
The Scientist and Jerome Siegel | Mar 1, 2016 | 10+ min read
Once believed to be unique to birds and mammals, sleep is found across the metazoan kingdom. Some animals, it seems, can’t live without it, though no one knows exactly why.
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.
Scientists from countries with fewer resources are pushing collaborators from higher-income countries to shed biases and behaviors that perpetuate social stratification in the research community.
Saliva tests screen staff and students at University of Illinois; Study ranks species most susceptible to SARS-CoV-2 infection; COVID-19 clinical trials test drugs that inhibit kinin system